LIPUM Stock Overview
A biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Lipum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 12.00 |
| 52 Week High | SEK 18.40 |
| 52 Week Low | SEK 5.50 |
| Beta | 0.15 |
| 1 Month Change | -16.08% |
| 3 Month Change | -10.45% |
| 1 Year Change | 84.05% |
| 3 Year Change | -39.39% |
| 5 Year Change | n/a |
| Change since IPO | -47.17% |
Recent News & Updates
Recent updates
Shareholder Returns
| LIPUM | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0.8% | 1.1% | 0.6% |
| 1Y | 84.0% | 14.6% | 4.2% |
Return vs Industry: LIPUM exceeded the Swedish Biotechs industry which returned 15.6% over the past year.
Return vs Market: LIPUM exceeded the Swedish Market which returned 4.5% over the past year.
Price Volatility
| LIPUM volatility | |
|---|---|
| LIPUM Average Weekly Movement | 8.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 5.5% |
| 10% most volatile stocks in SE Market | 11.5% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: LIPUM's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: LIPUM's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 5 | Ola Sandborgh | www.lipum.se |
Lipum AB (publ), a biopharmaceutical company, engages in the discovery and development of treatment for chronic inflammatory diseases in Sweden. It is developing SOL-116, a humanized antibody that is in late preclinical phase for the treatment of juvenile idiopathic arthritis and rheumatoid arthritis diseases. Lipum AB (publ) has a collaboration with Pelago Bioscience AB to focus on drug target monitoring during clinical studies of the lead candidate SOL-116; and a collaboration with the Karolinska Institute to explore the role of bile salt-stimulated lipase in the immune system in general and in rheumatoid arthritis in particular.
Lipum AB (publ) Fundamentals Summary
| LIPUM fundamental statistics | |
|---|---|
| Market cap | SEK 254.55m |
| Earnings (TTM) | -SEK 39.24m |
| Revenue (TTM) | SEK 53.00k |
4,803x
P/S Ratio-6.5x
P/E RatioIs LIPUM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LIPUM income statement (TTM) | |
|---|---|
| Revenue | SEK 53.00k |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 53.00k |
| Other Expenses | SEK 39.29m |
| Earnings | -SEK 39.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 26, 2025
| Earnings per share (EPS) | -1.85 |
| Gross Margin | 100.00% |
| Net Profit Margin | -74,037.74% |
| Debt/Equity Ratio | 24.7% |
How did LIPUM perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 04:51 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lipum AB (publ) is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kevin Sule | Redeye |